TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces that Dr. Marie Paule Richard, Chief Medical Officer of TiGenix, will be speaking at the 7th TERMIS-EU Industry Day taking place from June 26-30, 2017 at the Davos Conference Center, Switzerland.

Dr. Richard will give a presentation at an Industry Symposium on June 28 as part of a session entitled, Clinical evaluation road map and clinical development strategies.

 

During the coming months, representatives of TiGenix will also be attending the following conferences:

 

PDA-Advanced Therapy Medicinal Products

Date: June 27-28, 2017

Venue: SH Valencia Palace, Valencia, Spain

Attendee: Dr. Wilfried Dalemans, Chief Technical Officer, TiGenix NV

 

European Society of Cardiology (ESC) Congress

Date: August 26-30, 2017

Venue: Fira Gran Via, Barcelona, Spain

Attendee: Inmaculada Gilaberte Asin, Clinical Development Director & Manuel Luque, Senior Clinical Project Manager Allo-CSC 01, TiGenix SAU

 

Annual Symposium of the International Sepsis Forum

Date: 11-13 September, 2017

Venue: Institut Pasteur, Paris, France

Attendee: Jesus Gonzalez, Clinical Development Director Cx611, TiGenix SAU

 

Congress of the European Shock Society.

Date: 13-15 September, 2017

Venue: Institut Pasteur, Paris, France

Attendee: Jesus Gonzalez, Clinical Development Director Cx611, TiGenix SAU

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?